Biopharma M&A Intensifies Driven by Patent Cliffs and Pipeline Enhancement, Evolving Deal Structures with Increased CVRs

August 30, 2026

Endpoints News Global

Overview

Biopharma M&A activity is rapidly intensifying, spurred by the pressure of patent expirations and the necessity to fill pipeline gaps. Companies are accelerating acquisitions to secure new therapies and ensure future growth, exemplified by Roche’s up to $2.3 billion investment deal for Hanmi’s obesity candidate. Furthermore, deal structures are evolving, with an increasing adoption of Contingent Value Rights (CVRs) and deferred payments in acquisition considerations. This trend indicates a strategic shift within the industry to manage market uncertainties while ensuring access to innovative treatments.

In Depth

Key Findings

The biopharma industry’s M&A activity has shown a marked increase in the first half of 2026, driven by the need to counter revenue declines from patent expirations and bolster pipelines for future growth. A notable aspect of this trend is the evolution of acquisition deal structures, with a growing adoption of Contingent Value Rights (CVRs) and deferred payments linked to future outcomes. This approach allows acquiring companies to mitigate risks while securing access to promising assets.

Technical / Clinical Details

Recent key transaction examples include the partnership between ARCH and Population Health with Haisco, and Roche’s agreement to invest up to $2.3 billion in Hanmi Pharm’s obesity therapeutic candidate (which is detailed in another article). These deals are focused on specific high-growth therapeutic areas such as oncology, metabolic diseases, and rare diseases. The increase in CVRs functions as a strategy to defer payment obligations until the value of early-stage clinical assets or highly-valued assets contingent on regulatory approval or commercialization is de-risked and proven.

Background & Context

Many major pharmaceutical companies are facing patent expirations on key products, making the acquisition of biotechnology companies with innovative drug candidates essential to offset impending revenue losses. However, valuing biotech assets is challenging due to their high development risk and inherent uncertainties. In this context, flexible payment terms such as CVRs and deferred payments have become attractive solutions for both buyers and sellers, enabling investment in promising innovations despite market uncertainties.

Strategic Significance & Outlook

The intensification of M&A activity and the evolution of deal structures are expected to continue as major trends in the biopharma industry. Companies are anticipated to adopt more risk-diversified M&A strategies and actively utilize payment mechanisms linked to the commercial success of targeted assets. This movement will play a crucial role in bringing new technological innovations to market, particularly in areas like cell and gene therapy, AI-driven drug discovery, and personalized medicine. Industry consolidation and restructuring will be vital means to deliver new therapies to patients while generating attractive returns for investors.

Source: https://endpoints.news/topic-hub/biopharma-ma-and-dealmaking-whos-buying-and-why/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.